AstraZeneca

Pascal Soriot, Executive Director, Chief Executive Officer

33rd J.P. Morgan Healthcare Conference, San Francisco

14 January 2015



Cautionary statement regarding forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement:

This presentation contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted.

The forward-looking statements reflect knowledge and information available at the date of preparation of this presentation and AstraZeneca undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of patents, marketing exclusivity or trade marks, or the risk of failure to obtain patent protection; the risk of substantial adverse litigation/government investigation claims and insufficient insurance coverage; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the risk that strategic alliances and acquisitions will be unsuccessful; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of failure to manage a crisis; the risk of delay to new product launches; the difficulties of obtaining and maintaining regulatory approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; the risk of environmental liabilities; the risks associated with conducting business in emerging markets; the risk of reputational damage; the risk of product counterfeiting; the risk of failure to successfully implement planned cost reduction measures through productivity initiatives and restructuring programmes; the risk that regulatory approval processes for biosimilars could have an adverse effect on future commercial prospects; and the impact of increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation.

Nothing in this presentation should be construed as a profit forecast.

Completing the first phase of the journey

>$45bn
in 2023

2012-2014
Building strong foundations

2015-2017
Delivering on return to growth

2018+
Sustainable delivery and growth

Achieve scientific leadership:
R&D in 3 core therapeutic areas & across key platforms



Achieve scientific leadership:
Late-stage pipeline volume well ahead of plan

Targeted
Phase III & Registration NME pipeline volume (#)



Achieved/On track to achieve
Phase III & Registration NME pipeline volume (#)



Return to growth:
Upcoming submissions drive longer-term growth

LE submission opportunities				**MEDI4736 + tremelimumab** 2L SCCHN
			Faslodex 1L metastatic breast cancer	**MEDI4736** 2L SCCHN
			Brilinta stroke	***Lynparza*** BRCAm metastatic breast cancer
		saxa/dapa FDC type 2 diabetes	**brodalumab*** psoriatic arthritis	***Lynparza*** BRCAm PSR ovarian cancer (SOLO-2)
	Brilinta prior MI	***Bydureon*** autoinjector	**lesinurad FDC** gout	***Caprelsa*** differentiated thyroid cancer
NME submission opportunities		**CAZ AVI** serious infections	**roxadustat** CKD / ESRD (China)	**MET** papillary renal cell carcinoma
	brodalumab* psoriasis	**selumetinib** uveal melanoma	**benralizumab** severe asthma	**tremelimumab** mesothelioma
	PT003 (LAMA/LABA) COPD	**AZD9291** NSCLC	**PT001 (LAMA)** COPD	**MEDI4736** 3L NSCLC
	2015		**2016**	

*Partner Amgen to manage regulatory submission

Return to growth:
Oncology will become sixth growth platform

Several potential oncology submissions 2015-2016

MEDI4736
3L NSCLC

MET
papillary renal cell carcinoma

tremelimumab
mesothelioma

AZD9291
NSCLC

selumetinib
uveal melanoma

Oncology likely to become a key growth driver

- Several potential submissions and launches 2015-2016
- Contributes largest proportion of projected pipeline-driven revenue growth
- Potential to grow to almost a quarter of sales by 2023

Building a different shape of business

Higher probability of success, durability and profitability

Increasing biologics ~50% of pipeline	Increasing device products	Increasing specialty care
		
Greater durability Higher probability of success	Greater durability	Increasing profitability

Late-stage pipeline:
Key news flow through 2015

	Compound	Indication	Potential milestone
RIA	**brodalumab**	psoriasis	Regulatory submission
	PT003 (LAMA/LABA)	COPD	Phase III results & regulatory submission
	anifrolumab	SLE	Phase II presentation
	lesinurad	gout	Regulatory submission
CVMD	***Brilinta***	prior MI (PEGASUS)	Phase III results
	saxa/dapa FDC	type 2 diabetes	Regulatory submission
Oncology	***Lynparza***	PSR BRCAm ovarian cancer	Approval Phase III topline results (SOLO-2)
	AZD9291	2nd line NSCLC	Regulatory submission
	MEDI4736 (PD-L1)	3rd line NSCLC	Phase II/potential registration topline results
	MEDI4736 (PD-L1) / tremelimumab	NSCLC	Phase I presentation (ASCO)
	cediranib	ovarian cancer	Further analysis (ICON6)
Neuroscience	***Movantik/Moventig***	opioid-induced constipation	US de-scheduling & launch; EU approval

Key messages

- ✓ Strategy implementation on track
- ✓ Late-stage pipeline progressing ahead of plans
- ✓ Accelerating return to growth and ambition to become a >$45bn company by 2023
- ✓ Building a sustainable, durable and more profitable business
- ✓ Strong 2015 news flow expected

AstraZeneca

Pascal Soriot, Executive Director, Chief Executive Officer

33rd J.P. Morgan Healthcare Conference, San Francisco

14 January 2015